|
Treatment strategy
|
Total cost (USD)
|
Incremental cost (USD)
|
Total LY
|
LY saveda
|
ICER per LY saved
|
|---|
|
Vancomycin
|
15,254
| |
7.52
| | |
|
SXT/rifampicin
|
13,419
|
-1836
|
7.68
|
0.16
|
Dominant
|
|
Linezolid
|
16,387
|
1133
|
7.92
|
0.40
|
2833
|
|
Tedizolid
|
17,353
|
2099
|
7.90
|
0.38
|
5523
|
|
Daptomycin
|
17,238
|
1984
|
7.84
|
0.32
|
6200
|
|
Ceftaroline
|
17,971
|
2717
|
7.82
|
0.30
|
9057
|
- cSSSI complicated skin and soft structure infection, USD US dollar, LY life-years, ICER incremental cost-effectiveness ratio, SXT trimethoprim/sulfamethoxazole
- aCalculated as the average cost per patient and the average number of LY per patient in this strategy minus those of the treatment of vancomycin
